ArticleNature communications2026

A pharmacokinetic and pharmacodynamic drug-drug interaction study of dorzagliatin and empagliflozin in patients with type 2 diabetes and obesity: an open-label phase I trial.

Huan Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.